The WSJ today penned the headline Pfizer Is Dealt Setback On HIV-Drug Approval.
In the article the WSJ wrote about the new drug maraviroc: "Pfizer Inc.'s pipeline was dealt a surprise blow last night, when the FDA delayed the approval of one of its most interesting drug prospects, a new type of medicine for HIV."
The WSJ also said that "The FDA isn't asking for any more clinical trials."
The FDA apparently couldn't be reached for comment last night.
So did the allegations related to illegal premarketing of maraviroc result in this debacle?
Make up your own mind and read all the maraviroc allegations by Pfizer's internal whistleblower here.
Peter Rost, M.D., is a former Pfizer Marketing Vice President providing services as a medical device and drug expert witness and pharmaceutical marketing expert. Judge Sanders: "The court agrees with defendants' view that Dr. Rost is a very adept and seasoned expert witness." He is also the author of Emergency Surgery, The Whistleblower and Killer Drug. You can reach him on rostpeter (insert symbol) hotmail.com. Follow on https://twitter.com/peterrost
Thursday, June 21, 2007
Did Pfizer's maraviroc whistleblower delay FDA approval of HIV drug?
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment